• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Cochrane 10.4.2011

IDSearchHits
#1“Arthritis, Rheumatoid”[Mesh] OR ankylosing spondylitis OR ankylosing arthritis OR “Arthritis, Psoriatic”[Mesh] OR “Crohn Disease”[Mesh] OR “Colitis, Ulcerative”[Mesh] OR “Arthritis, Juvenile Rheumatoid”[Mesh] OR juvenile idiopathic arthritis OR “plaque psoriasis”[All Fields] OR (“Plaque”[All Fields] AND (“psoriasis”[MeSH] OR “psoriasis”[All Fields]))6649
#2(#1), in 201171
#3abatacept”[Substance Name] OR “abatacept”[All Fields] OR “Orencia”[All Fields] OR 332348-12-6[rn]67
#4adalimumab”[Substance Name] OR “adalimumab”[All Fields] OR “Humira”[All Fields] OR 331731-18-1[rn]241
#5alefacept”[Substance Name] OR “alefacept”[All Fields] OR “Amevive”[All Fields] OR 222535-22-0[rn]110
#6“Interleukin 1 Receptor Antagonist Protein”[Mesh] OR “Anakinra”[All Fields] OR “Kineret”[All Fields] OR 143090-92-0[rn]148
#7“CDP870”[Substance Name] OR “Certolizumab”[All Fields] OR “Cimzia”[All Fields] OR 428863-50-7[rn]43
#8“TNFR-Fc fusion protein”[Substance Name] OR “etanercept”[All Fields] OR “Enbrel”[All Fields] OR 185243-69-0[rn]474
#9infliximab”[Substance Name] OR “infliximab”[All Fields] OR “Remicade”[All Fields] OR 170277-31-3[rn]581
#10natalizumab”[Substance] OR “natalizumab”[All Fields] OR “Tysabri”[All Fields]87
#11rituximab”[Substance Name] OR “rituximab”[All Fields] OR “Rituxan”[All Fields] OR 174722-31-7[rn]619
#12tocilizumab”[Substance Name] OR “actemra”[All Fields] OR “RoActemra”[All Fields] OR 375823-41-9[rn]30
#13“monoclonal antibody CNTO 1275 “[Substance Name] OR “ustekinumab”[All Fields] OR “Stelara”[All Fields] OR 815610-63-0[rn]22
#14golimumab”[Supplementary Concept] OR “golimumab”[All Fields] OR “simponi”[All Fields]33
#15(#2 AND ( #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 ))22
#16“Treatment Outcome”[Mesh] OR outcome OR efficacy OR effectiveness OR adverse OR safety OR withdrawal* OR harm OR mortality OR morbidity OR function* OR toxicity352094
#17(#15 AND #16)21

From: Appendix B, Search strategy

Cover of Drug Class Review: Targeted Immune Modulators
Drug Class Review: Targeted Immune Modulators: Final Update 3 Report [Internet].
Thaler KJ, Gartlehner G, Kien C, et al.
Portland (OR): Oregon Health & Science University; 2012 Mar.
Copyright © 2012, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.